1 / 4

Working together to rationalize the use of Anti-TB drugs

Working together to rationalize the use of Anti-TB drugs. GROUP 5 Facilitators: Dr Andrey Zagorkiy, MSH and Dr Knut Lönnroth, WHO/HQ. Summary of Discussion. Great variation in country scenarios: One extreme: NTP monopoly, TB drugs not available in private market, no domestic market

erin-fletcher
Download Presentation

Working together to rationalize the use of Anti-TB drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Working together to rationalize the use of Anti-TB drugs GROUP 5 Facilitators: Dr Andrey Zagorkiy, MSH and Dr Knut Lönnroth, WHO/HQ

  2. Summary of Discussion • Great variation in country scenarios: • One extreme: NTP monopoly, TB drugs not available in private market, no domestic market • Other extreme: Private sector dominates 1st and 2nd line drugs, NTP controls fraction, huge domestic market that is protected by domestic laws, everything available in private markets, (with or without prescription) • Lack of data on magnitude, quality of prescription, quality of drugs, in relation to treatment outcome (and ADR) • Any effort to improve RUD requires involvement beyond NTP, wider health systems and regulatory issue • We mapped role of professional association along the steps of rational use: Quality prescription – drug quality – quality of dispensing – quality supervision, recording and reporting (including ADR)

  3. Activities for professional associations to contribute to rational use of TB drugs

  4. Conclusion • Need for country and regional specific approaches • Need of better data on current situation • Important to map and involve wide range of professional associations and other stakeholders outside NTP to improve rational use of drugs • Involve these stakeholders in development of NTP plans, including MDR national plans (for example in 27 MDR high priority countries in preparation for the MDR meeting in China)

More Related